(Q38468745)

3 September 2017

1 reference

title

Antipsychotic medication in schizophrenia: a review (English)

1 reference

3 September 2017

0 references

John Lally

1

0 references

James H. MacCabe

object named as

James H MacCabe

series ordinal

2

0 references

publication date

8 May 2015

1 reference

3 September 2017

published in

British Medical Bulletin

1 reference

3 September 2017

volume

114

1 reference

3 September 2017

issue

1

1 reference

3 September 2017

page(s)

169-179

1 reference

Role of dopamine D(2) receptors for antipsychotic activity

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Schizophrenia: an integrated sociodevelopmental-cognitive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Treatment of the neuroleptic-nonresponsive schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Almost all antipsychotics result in weight gain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Compliance with medication regimens for mental and physical disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Challenges in the treatment of major depressive disorder with psychotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

Asenapine review, part II: clinical efficacy, safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBMB%2FLDV017

21 January 2018

Identifiers

DOI

10.1093/BMB/LDV017

1 reference

3 September 2017

1 reference